Abstract
Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss syndrome (CSS), is a small vessel vasculitis associated with eosinophilia and asthma. Clinical manifestations commonly seen in patients presenting with EGPA range from upper airway and lung involvement to neurological, cardiac, cutaneous, and renal manifestations. Treatment for severe presentations includes steroids, cyclophosphamide, plasmapheresis, and recently, rituximab. Rituximab is associated with a good response in the treatment of vasculitis, but a variable response for the control of allergic symptoms. Here, we report a 16-year-old female patient with severe EGPA (gastrointestinal and cutaneous vasculitis, rhinitis and asthma) refractory to conventional treatment. She was treated with rituximab, which enabled rapid control of the vasculitis component of the disease, but there was no response to rhinitis and asthma. Additionally, she developed severe bronchospasm during rituximab infusion. Sequential rituximab and omalizumab were initiated, leading to remission of all manifestations of vasculitis, rhinitis, and asthma, in addition to bronchospasm related to rituximab infusion.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Unizony SH, Stone, JH (2015) 157- Antineutrophil cytoplasmic antibody–associated vasculitis. In: Silman AJ, Smolen JS, Weinblatt ME, Weisman M (eds) MHBTR, 6th edn. Elsevier Ltd., Philadelphia, pp 1310–1321
Greco A, Ida M, De Virgilio A, Gallo A, Fusconi M, Ruoppolo G et al (2015) Autoimmunity reviews Churg–Strauss syndrome. Autoimmun Rev 14:341–348. doi:10.1016/j.autrev.2014.12.004
Vaglio A, Moosig F, Zwerina J Churg-Strauss syndrome: update on pathophysiology and treatment. Curr Opin Rheumatol 24:24–30. doi:10.1097/BOR.0b013e32834d85ce
Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T et al (2016) (2012) EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 75:1583–1594. doi:10.1136/annrheumdis-2016-209133
Mohammad AJ, Hot A, Arndt F, Moosig F, Guerry M-J, Amudala N et al (2016) Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann Rheum Dis 75:396–401. doi:10.1136/annrheumdis-2014-206095
Bouldouyre M-A, Cohen P, Guillevin L (2009) Severe bronchospasm associated with rituximab for refractory Churg-Strauss syndrome. Ann Rheum Dis 68:606. doi:10.1136/ard.2008.093773
Ramírez LF, Canas CA, Tobon GJ, Bonilla F, Serrano CD (2013) Successful desensitisation to rituximab in four patients with autoimmune diseases. Allergy Eur J Allergy Clin Immunol 68:211–212
Baldini C, Talarico R (2010) Clinical manifestations and treatment of Churg-Strauss syndrome. Rheum Dis Clin N Am 36:527–543. doi:10.1016/j.rdc.2010.05.003
Cartin-Ceba R, Golbin JM, Keogh KA, Peikert T, Sanchez-Menendez M, Ytterberg SR et al (2012) Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener’s): ten-year experience at a single center. Arthritis Rheum 64:3770–3778. doi:10.1002/art.34584
Jachiet M, Samson M, Cottin V, Kahn J-E, Le Guenno G, Bonniaud P et al (2016) Anti-IgE monoclonal antibody (omalizumab) in refractory and relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss): data on seventeen patients. Arthritis Rheumatol 68:2274–2282. doi:10.1002/art.39663
Noga O, Hanf G, Brachmann I, Klucken AC, Kleine-Tebbe J, Rosseau S et al (2006) Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol 117:1493–1499. doi:10.1016/j.jaci.2006.02.028
Yong PFK, Malik R, Arif S, Peakman M, Amiel S, Ibrahim MAA et al (2009) Rituximab and omalizumab in severe, refractory insulin allergy. N Engl J Med 360:1045–1047. doi:10.1056/NEJMc0808282
Busse W, Spector S, Rosén K, Wang Y, Alpan O (2013) High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. J Allergy Clin Immunol 132:485–486.e11. doi:10.1016/j.jaci.2013.02.032
Sánchez-Ramon S, Eguiluz-Gracia I, Rodríguez-Mazariego ME, Paravisini A, Zubeldia-Ortuno JM, Gil-Herrera J et al (2013) Sequential combined therapy with omalizumab and rituximab: a new approach to severe atopic dermatitis. J Investig Allergol Clin Immunol 23:190–196
Iglesias E, Camacho Lovillo M, Delgado Pecellin I, Lirola Cruz MJ, Falcon Neyra MD, Salazar Quero JC et al (2014) Successful management of Churg-Strauss syndrome using omalizumab as adjuvant immunomodulatory therapy: first documented pediatric case. Pediatr Pulmonol 49:E78–E81. doi:10.1002/ppul.22884
Borekci S, Aydin O, Hatemi G, Gemicioglu B (2015) Development of eosinophilic granulomatosis with poliangiitis (Churg-Strauss syndrome) and brain tumor in a patient after more than 7 years of omalizumab use: a case report. Int J Immunopathol Pharmacol 28:134–137. doi:10.1177/0394632015572567
Nazir S, Tachamo N, Fareedy SB, Khan MS, Lohani S (2017) Omalizumab-associated eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Ann Allergy Asthma Immunol 118:372–374.e1. doi:10.1016/j.anai.2016.12.003
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
None.
Rights and permissions
About this article
Cite this article
Aguirre-Valencia, D., Posso-Osorio, I., Bravo, JC. et al. Sequential rituximab and omalizumab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Clin Rheumatol 36, 2159–2162 (2017). https://doi.org/10.1007/s10067-017-3780-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-017-3780-9